Bussiness1 month ago
TME Pharma Reports H1 2024 Financial Results and Provides Business and Clinical Update
Statistically significant survival benefit of NOX-A12 + bevacizumab + radiotherapy for glioblastoma patients compared to both standard of care and NOX-A12 + radiotherapy demonstrated by latest...
